Filing Details

Accession Number:
0000874015-24-000072
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-18 17:44:05
Reporting Period:
2024-01-16
Accepted Time:
2024-01-18 17:44:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874015 Ionis Pharmaceuticals Inc IONS Pharmaceutical Preparations (2834) 330336973
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1813775 Joseph Baroldi 2855 Gazelle Court
Carlsbad CA 92010
Evp, Chief Business Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-16 3,688 $0.00 14,259 No 4 M Direct
Common Stock Disposition 2024-01-17 1,460 $50.42 12,799 No 4 S Direct
Common Stock Acquisiton 2024-01-16 1,353 $0.00 2,204 No 4 M Indirect by Spouse
Common Stock Disposition 2024-01-17 564 $50.42 1,640 No 4 S Indirect by Spouse
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Indirect by Spouse
No 4 S Indirect by Spouse
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Unit Disposition 2024-01-16 3,688 $0.00 3,688 $0.00
Common Stock Restricted Stock Unit Disposition 2024-01-16 1,353 $0.00 1,353 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
63,973 No 4 M Direct
7,034 No 4 M Indirect
Footnotes
  1. Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
  2. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
  3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.35 to $50.43, inclusive. The reporting person undertakes to provide to IonisPharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.
  4. Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
  5. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
  6. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.